Non-invasive tests for predicting liver outcomes in chronic hepatitis C patients: A systematic review and meta-analysis

Table 3 Area under the receiver operating characteristic curves of non-invasive tests for overall mortality, liver-related mortality, and composite outcomes

Ref.	NIT1	Outcome	AUROC (95%CI)
Chalouni et al[18], 2019	APRI	OM	0.58 (N/A)
		LRM	0.80 (N/A)
		LRE	0.75 (N/A)
	FIB-4	OM	0.66 (N/A)
		LRM	0.88 (N/A)
		LRE	0.78 (N/A)
	TE	OM	0.69 (N/A)
		LRM	0.88 (N/A)
		LRE	0.88 (N/A)
Hansen et al[20], 2019	TE	OM	0.70 (0.62–0.78)
		LRM	0.93 (0.89–0.98)
		HD (HCC included)	0.89 (0.82–0.97)
Munteanu et al[22], 2018	Fibrotest	OM	0.74 (0.71-0.77)
		LRM	0.88 (0.85-0.90)
Thandassery et al[43], 2017	APRI (Pre-Rx)	HD	0.54 (0.06–0.78)
	FIB-4 (Pre-Rx)	HD	0.85 (0.74–0.96)
Pérez-Latorre et al[24], 2016	TE	OM	Estimation cohort 0.87 (0.84-0.90)
			Validation cohort 0.88 (0.84-0.91)
Lee et al[46], 2016	TE (Post-Rx)	A composite outcome of HD, HCC, and/or LRM	0.92 (0.84-1.00)
Berenguer et al[12], 2015	FIB-4 (Pre-Rx)	LRE (HD or HCC)	0.75 (0.72-0.78)
Yu et al[11], 2006	APRI (Pre-Rx)	OM	0.53 (0.35-0.72)
	APRI (Post-Rx)	OM	0.87 (0.81-0.93)

¹NITs are not classified as either pre-treatment or post-treatment once the study did not specify when the NIT measurement regarding the initiation of hepatitis C virus therapy was done. N/A: Not available; APRI: Aspartate aminotransferase to platelet ratio index; FIB-4: Fibrosis-4 index; HCC: Hepatocellular carcinoma; HD: Hepatic decompensation; LSM: Liver stiffness measurement; LRM: Liver-related mortality; LRE: Liver-related event; NIT: Non-invasive test; OM: Overall mortality; pre-Rx: Pre-treatment; post-Rx: Post-treatment; AUROC: Area under the receiver operating characteristic curves; TE: Transient elastography.